Dolutegravir vs Elvitegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)

Marketed by GlaxoSmithKline and partners

Approved in HIVsmall molecule
Reliable signal

NCT01263015 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). (met)

Result source: NCT01263015

Elvitegravir · Stribild

Marketed by Gilead Sciences and partners

Approved in HIVsmall molecule
Partial signal

NCT01095796 · Phase 3 · completed

Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.

Reported efficacy

The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)

Result source: NCT01095796

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDolutegravirElvitegravir
HIV-1 RNA below 50 copies/mL (week 48)88% vs 85%vs RTG50 mg Once a Day · wk 48 · n 411NCT01227824
12 other results
  • 90% vs 83% 50 mg once daily · wk 48 · n 242 · Phase 3 · primary NCT01449929
  • 88% vs 81% 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · primary NCT01263015
  • 90% vs 93% wk 48 · n 356 · Phase 3 · primary NCT02831673
  • 93% vs 94% wk 48 · n 360 · Phase 3 · primary NCT02831764
  • 71% vs 63% 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 77% vs 70% 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 79% vs 83% wk 144 · n 356 · Phase 3 · secondary NCT02831673
  • 84% vs 84% wk 144 · n 360 · Phase 3 · secondary NCT02831764
  • 84% vs 89% wk 96 · n 356 · Phase 3 · secondary NCT02831673
  • 88% vs 90% wk 96 · n 360 · Phase 3 · secondary NCT02831764
  • 92% vs 93% wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 94% vs 94% wk 24 · n 360 · Phase 3 · secondary NCT02831764
87.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT01837277—Not reported
CD4 count, change (week 48)163 vs 174−11 vs placebo50 mg BID · wk 72 · n 14NCT01568892
44 other results
  • 170 vs 146 50 mg BID · wk 60 · n 14 · Phase 3 · secondary NCT01568892
  • 115 vs 156 50 mg BID · wk 48 · n 14 · Phase 3 · secondary NCT01568892
  • 90.5 vs 125.5 50 mg BID · wk 40 · n 14 · Phase 3 · secondary NCT01568892
  • 48 vs 135.5 50 mg BID · wk 32 · n 14 · Phase 3 · secondary NCT01568892
  • 39 vs 117 50 mg BID · wk 24 · n 14 · Phase 3 · secondary NCT01568892
  • 292.2 vs 286.2 50 mg Once a Day · wk 96 · n 411 · Phase 3 · secondary NCT01227824
  • 281.3 vs 292.9 50 mg Once a Day · wk 84 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 278.6 50 mg Once a Day · wk 72 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 264.2 50 mg Once a Day · wk 60 · n 411 · Phase 3 · secondary NCT01227824
  • 238.9 vs 257.5 50 mg Once a Day · wk 48 · n 411 · Phase 3 · secondary NCT01227824
  • 248.8 vs 230.7 wk 48 · n 248 · Phase 3 · secondary NCT01910402
  • 224.1 vs 239.8 50 mg Once a Day · wk 40 · n 411 · Phase 3 · secondary NCT01227824
  • 230.7 vs 191.4 wk 36 · n 248 · Phase 3 · secondary NCT01910402
  • 223.4 vs 241.3 50 mg Once a Day · wk 32 · n 411 · Phase 3 · secondary NCT01227824
  • 199.3 vs 204.2 50 mg Once a Day · wk 24 · n 411 · Phase 3 · secondary NCT01227824
  • 200.6 vs 163 wk 24 · n 248 · Phase 3 · secondary NCT01910402
  • 378.5 vs 331.6 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 379.5 vs 333.3 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 377.9 vs 327.2 50 mg plus 600/300 mg once daily · wk 132 · n 414 · Phase 3 · secondary NCT01263015
  • 347 vs 311 50 mg plus 600/300 mg once daily · wk 120 · n 414 · Phase 3 · secondary NCT01263015
  • 349.3 vs 298.9 50 mg plus 600/300 mg once daily · wk 108 · n 414 · Phase 3 · secondary NCT01263015
  • 322.6 vs 286 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 315.2 vs 272.1 50 mg plus 600/300 mg once daily · wk 84 · n 414 · Phase 3 · secondary NCT01263015
  • 306.1 vs 269.6 50 mg plus 600/300 mg once daily · wk 72 · n 414 · Phase 3 · secondary NCT01263015
  • 271.3 vs 235.3 50 mg plus 600/300 mg once daily · wk 60 · n 414 · Phase 3 · secondary NCT01263015
  • 267.5 vs 209.5 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · secondary NCT01263015
  • 265.5 vs 216.2 50 mg plus 600/300 mg once daily · wk 40 · n 414 · Phase 3 · secondary NCT01263015
  • 250.5 vs 208.1 50 mg plus 600/300 mg once daily · wk 32 · n 414 · Phase 3 · secondary NCT01263015
  • 216.9 vs 177.8 50 mg plus 600/300 mg once daily · wk 24 · n 414 · Phase 3 · secondary NCT01263015
  • 301.8 vs 303.2 wk 144 · n 270 · Phase 3 · secondary NCT02831673
  • 301.7 vs 296.6 wk 144 · n 296 · Phase 3 · secondary NCT02831764
  • 264.7 vs 253.8 wk 96 · n 301 · Phase 3 · secondary NCT02831673
  • 272 vs 264.6 wk 96 · n 318 · Phase 3 · secondary NCT02831764
  • 265 vs 230 wk 96 · n 350 · Phase 2/3 · secondary NCT02259127
  • 311 vs 230 wk 96 · n 154 · Phase 2/3 · secondary NCT02259127
  • 228 vs 230 wk 96 · n 196 · Phase 2/3 · secondary NCT02259127
  • 222.2 vs 217.7 wk 48 · n 356 · Phase 3 · secondary NCT02831673
  • 225.7 vs 217.2 wk 48 · n 360 · Phase 3 · secondary NCT02831764
  • 192.2 vs 175.1 wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 188.8 vs 163.2 wk 24 · n 360 · Phase 3 · secondary NCT02831764
  • 72 vs 230 wk 96 · n 42 · Phase 2/3 · secondary NCT02259127
  • 39 vs 28 wk 48 · n 40 · Phase 3 · secondary NCT02263326
  • 88 vs 75 wk 24 · n 65 · Phase 2 · secondary NCT03991013
  • 111 vs 101 wk 24 · n 52 · Phase 2 · secondary NCT03851588
321 vs 300vs Atriplawk 144 · n 348NCT01095796
26 other results
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 295 vs 273 wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 360 vs 328 wk 192 · n 348 · Phase 3 · secondary NCT01095796
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 239 vs 206 wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557

HIV-1 RNA below 50 copies/mL (week 48)

Dolutegravir
88% vs 85%vs RTG50 mg Once a Day · wk 48 · n 411NCT01227824
12 other results
  • 90% vs 83% 50 mg once daily · wk 48 · n 242 · Phase 3 · primary NCT01449929
  • 88% vs 81% 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · primary NCT01263015
  • 90% vs 93% wk 48 · n 356 · Phase 3 · primary NCT02831673
  • 93% vs 94% wk 48 · n 360 · Phase 3 · primary NCT02831764
  • 71% vs 63% 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 77% vs 70% 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 79% vs 83% wk 144 · n 356 · Phase 3 · secondary NCT02831673
  • 84% vs 84% wk 144 · n 360 · Phase 3 · secondary NCT02831764
  • 84% vs 89% wk 96 · n 356 · Phase 3 · secondary NCT02831673
  • 88% vs 90% wk 96 · n 360 · Phase 3 · secondary NCT02831764
  • 92% vs 93% wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 94% vs 94% wk 24 · n 360 · Phase 3 · secondary NCT02831764
Elvitegravir
87.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557

HIV-1 RNA 50 copies/mL or more (week 48)

Dolutegravir
—Not posted · NCT01837277
Elvitegravir
—Not reported

CD4 count, change (week 48)

Dolutegravir
163 vs 174−11 vs placebo50 mg BID · wk 72 · n 14NCT01568892
44 other results
  • 170 vs 146 50 mg BID · wk 60 · n 14 · Phase 3 · secondary NCT01568892
  • 115 vs 156 50 mg BID · wk 48 · n 14 · Phase 3 · secondary NCT01568892
  • 90.5 vs 125.5 50 mg BID · wk 40 · n 14 · Phase 3 · secondary NCT01568892
  • 48 vs 135.5 50 mg BID · wk 32 · n 14 · Phase 3 · secondary NCT01568892
  • 39 vs 117 50 mg BID · wk 24 · n 14 · Phase 3 · secondary NCT01568892
  • 292.2 vs 286.2 50 mg Once a Day · wk 96 · n 411 · Phase 3 · secondary NCT01227824
  • 281.3 vs 292.9 50 mg Once a Day · wk 84 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 278.6 50 mg Once a Day · wk 72 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 264.2 50 mg Once a Day · wk 60 · n 411 · Phase 3 · secondary NCT01227824
  • 238.9 vs 257.5 50 mg Once a Day · wk 48 · n 411 · Phase 3 · secondary NCT01227824
  • 248.8 vs 230.7 wk 48 · n 248 · Phase 3 · secondary NCT01910402
  • 224.1 vs 239.8 50 mg Once a Day · wk 40 · n 411 · Phase 3 · secondary NCT01227824
  • 230.7 vs 191.4 wk 36 · n 248 · Phase 3 · secondary NCT01910402
  • 223.4 vs 241.3 50 mg Once a Day · wk 32 · n 411 · Phase 3 · secondary NCT01227824
  • 199.3 vs 204.2 50 mg Once a Day · wk 24 · n 411 · Phase 3 · secondary NCT01227824
  • 200.6 vs 163 wk 24 · n 248 · Phase 3 · secondary NCT01910402
  • 378.5 vs 331.6 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 379.5 vs 333.3 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 377.9 vs 327.2 50 mg plus 600/300 mg once daily · wk 132 · n 414 · Phase 3 · secondary NCT01263015
  • 347 vs 311 50 mg plus 600/300 mg once daily · wk 120 · n 414 · Phase 3 · secondary NCT01263015
  • 349.3 vs 298.9 50 mg plus 600/300 mg once daily · wk 108 · n 414 · Phase 3 · secondary NCT01263015
  • 322.6 vs 286 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 315.2 vs 272.1 50 mg plus 600/300 mg once daily · wk 84 · n 414 · Phase 3 · secondary NCT01263015
  • 306.1 vs 269.6 50 mg plus 600/300 mg once daily · wk 72 · n 414 · Phase 3 · secondary NCT01263015
  • 271.3 vs 235.3 50 mg plus 600/300 mg once daily · wk 60 · n 414 · Phase 3 · secondary NCT01263015
  • 267.5 vs 209.5 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · secondary NCT01263015
  • 265.5 vs 216.2 50 mg plus 600/300 mg once daily · wk 40 · n 414 · Phase 3 · secondary NCT01263015
  • 250.5 vs 208.1 50 mg plus 600/300 mg once daily · wk 32 · n 414 · Phase 3 · secondary NCT01263015
  • 216.9 vs 177.8 50 mg plus 600/300 mg once daily · wk 24 · n 414 · Phase 3 · secondary NCT01263015
  • 301.8 vs 303.2 wk 144 · n 270 · Phase 3 · secondary NCT02831673
  • 301.7 vs 296.6 wk 144 · n 296 · Phase 3 · secondary NCT02831764
  • 264.7 vs 253.8 wk 96 · n 301 · Phase 3 · secondary NCT02831673
  • 272 vs 264.6 wk 96 · n 318 · Phase 3 · secondary NCT02831764
  • 265 vs 230 wk 96 · n 350 · Phase 2/3 · secondary NCT02259127
  • 311 vs 230 wk 96 · n 154 · Phase 2/3 · secondary NCT02259127
  • 228 vs 230 wk 96 · n 196 · Phase 2/3 · secondary NCT02259127
  • 222.2 vs 217.7 wk 48 · n 356 · Phase 3 · secondary NCT02831673
  • 225.7 vs 217.2 wk 48 · n 360 · Phase 3 · secondary NCT02831764
  • 192.2 vs 175.1 wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 188.8 vs 163.2 wk 24 · n 360 · Phase 3 · secondary NCT02831764
  • 72 vs 230 wk 96 · n 42 · Phase 2/3 · secondary NCT02259127
  • 39 vs 28 wk 48 · n 40 · Phase 3 · secondary NCT02263326
  • 88 vs 75 wk 24 · n 65 · Phase 2 · secondary NCT03991013
  • 111 vs 101 wk 24 · n 52 · Phase 2 · secondary NCT03851588
Elvitegravir
321 vs 300vs Atriplawk 144 · n 348NCT01095796
26 other results
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 295 vs 273 wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 360 vs 328 wk 192 · n 348 · Phase 3 · secondary NCT01095796
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 239 vs 206 wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Dolutegravir: 10 of 10 rows · Elvitegravir: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDolutegravir
Rows use multiple source trials
Elvitegravir
Rows use multiple source trials
CD4+
absolute change · cells/uL
No placebo or comparator arm
110 cells/uL @ 48wk50 mg BIDa,b,c
NCT01328041 · Phase 3
229 cells/uL @ 48wka,b,c
NCT01721109 · Phase 2/3 · registry result, not featured evidence
HIV-1 RNA
absolute change · log
Maintenance
-2.99 vs -3.06 EFV/TDF/FTC log @ 96wk50 mg plus 600/300 mg once dailyd
NCT01263015 · Phase 3 · combination · HIV · phase 3
1 other source trial
-2.938 vs -2.901 RTG log @ 96wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.26 vs -2.31 Raltegravir log @ 96wkd
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
HIV-1 RNA
absolute change · log
No placebo or comparator arm
-2.321 log @ 48wk50 mg BIDa,b,c
NCT01328041 · Phase 3
-3.16 log @ 48wka,b,c
NCT01721109 · Phase 2/3 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies
responder rate · % of participants
Maintenance
92% (n=242) vs 87% (n=242) DRV + RTV @ 48wk50 mg once dailyb,c
NCT01449929 · Phase 3
68.1% (n=351) vs 67.2% (n=351) Raltegravir @ 48wke,b,c
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
show 1 more dose
70.1% (n=351) vs 72.1% (n=351) Raltegravir @ 48wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
HIV-1 RNA Less Than 50
event count · % of participants
No placebo or comparator arm
68.9% (n=183) @ 24wk*50 mg BIDf,b,c
NCT01328041 · Phase 3 · converted to % from 126 participants as posted
95.2% (n=21) @ 24wk*f,b,c
NCT02477527 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
HIV-1 RNA LT 50 Copies
responder rate · % of participants
No placebo or comparator arm
100% (n=149) @ 432wkb,c
NCT01910402 · Phase 3 · registry result, not featured evidence
94.6% (n=223)e,b,c
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more doses
94.6% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
90.8% (n=447)
NCT02397096 · Phase 3 · registry result, not featured evidence
93.7% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
Dropout rate
17.4%50 mg plus 600/300 mg once dailyg
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
26%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
13.6%50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
31.1%50 mg BID
NCT01328041 · Phase 3
8.5%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
10.7%
NCT04585737 · Phase 4 · registry result, not featured evidence
25.6%Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
13.1%Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
—DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
17.6%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
—DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
16.2%DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
11.4%DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
7.8%Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
4.7%Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
15.4%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
0%50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
0%Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
0%Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
23.9%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
0%50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
6.7%50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
1.5%
NCT03991013 · Phase 2 · registry result, not featured evidence
3.8%
NCT03851588 · Phase 2 · registry result, not featured evidence
—Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
83.6%h
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
22.2%
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
6.3%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
20%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
5.4%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
16%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
43.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
12.3%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
12.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
10.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.9%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
80.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
0%
NCT01533259 · Phase 3 · registry result, not featured evidence
14%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
5.3%
NCT01497899 · Phase 2 · registry result, not featured evidence
6.3%
NCT00869557 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.1%50 mg plus 600/300 mg once dailyg
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
2.9%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
2.1%50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
3.8%50 mg BID
NCT01328041 · Phase 3
—
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
—
NCT04585737 · Phase 4 · registry result, not featured evidence
—Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
—Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
—DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
4%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
—DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
2.8%DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
2.8%DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
—Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
—
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
7.7%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
—50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—
NCT01837277 · Phase 2/3 · registry result, not featured evidence
—50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
—50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
—
NCT03991013 · Phase 2 · registry result, not featured evidence
—
NCT03851588 · Phase 2 · registry result, not featured evidence
—Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
2.5%h
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
—
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
0.4%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
1.6%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
0.9%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0.9%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
6.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
0.7%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
2.5%
NCT01106586 · Phase 3 · registry result, not featured evidence
—
NCT01533259 · Phase 3 · registry result, not featured evidence
—
NCT01721109 · Phase 2/3 · registry result, not featured evidence
0.9%
NCT01497899 · Phase 2 · registry result, not featured evidence
—
NCT00869557 · Phase 2 · registry result, not featured evidence
Serious AEs
15.7%50 mg plus 600/300 mg once dailyg
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
10%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
6.2%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg once daily
NCT01449929 · Phase 3
14.9%50 mg once daily
NCT01449929 · Phase 3
3.3%50 mg once daily
NCT01449929 · Phase 3
25.1%50 mg BID
NCT01328041 · Phase 3
9.9%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
8.1%
NCT04585737 · Phase 4 · registry result, not featured evidence
7.7%Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
8.2%Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
8.7%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
4.8%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
2.1%DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
10.4%DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
3.6%DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
10.8%DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
18%Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
18.1%Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
15.4%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
—50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
35.7%50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
26.2%Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
10%Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
14.9%Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
6.1%Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
9.8%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
6.9%50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
6.7%50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
3.1%
NCT03991013 · Phase 2 · registry result, not featured evidence
0%
NCT03851588 · Phase 2 · registry result, not featured evidence
0%Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
7.1%Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
19.8%h
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
0%
NCT02477527 · Phase 4 · registry result, not featured evidence
1.9%DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
6.4%DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.5%DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
2.3%DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
2.9%ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
2.6%ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
9.3%ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.3%ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
3.6%ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
3%Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
5.2%Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
8.2%Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
12.5%E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
2.8%Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
1.7%Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
5.3%DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
8.7%Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
9.1%
NCT02616783 · Phase 3 · registry result, not featured evidence
16.8%Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
20.6%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
15.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
18.2%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
8.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
8.9%All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.2%Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
16.4%
NCT01106586 · Phase 3 · registry result, not featured evidence
2.1%
NCT01533259 · Phase 3 · registry result, not featured evidence
10%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
10.7%
NCT01497899 · Phase 2 · registry result, not featured evidence
4.2%
NCT00869557 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
50 mg plus 600/300 mg once dailyg
diarrhoea 22.7%
nasopharyngitis 20.8%
insomnia 17.9%
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 31 more results
50 mg Once a Day
nausea 14.6%
diarrhoea 14.1%
headache 13.6%
NCT01227824 · Phase 3 · HIV · phase 3
50 mg Once a Day
upper respiratory tract infection 8%
syphilis 7.1%
viral upper respiratory tract infection 7.1%
NCT01227824 · Phase 3 · HIV · phase 3
50 mg once daily
diarrhoea 17.8%
headache 16.5%
nausea 16.5%
NCT01449929 · Phase 3
50 mg once daily
viral upper respiratory tract infection 4.1%
gastroenteritis 2.4%
asthenia 1.6%
NCT01449929 · Phase 3
50 mg BID
diarrhoea 22.4%
cough 15.8%
nausea 14.2%
NCT01328041 · Phase 3
insomnia/nightmares 3.9%
alopecia 2%
itching/rash/prurigo 2%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
nausea 4.7%
fatigue 4%
diarrhea 3.4%
NCT04585737 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 8.7%
headache 8.1%
urinary tract infection 6%
NCT01910402 · Phase 3 · registry result, not featured evidence
nausea 18.5%
headache 11.7%
diarrhoea 9.3%
NCT01910402 · Phase 3 · registry result, not featured evidence
covid-19 6.9%
suspected covid-19 3.4%
headache 3%
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
headache 14.3%
diarrhoea 14%
nasopharyngitis 13.8%
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
covid-19 6%
syphilis 4%
respiratory tract infection viral 3.2%
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 13.6%
upper respiratory tract infection 13.1%
nasopharyngitis 12.2%
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
creatinine renal clearance decreased 83.9%
blood creatinine increased 78.3%
haemoglobin decreased 3.7%
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
creatinine renal clearance decreased 89.8%
blood creatinine increased 83.3%
haemoglobin decreased 9.3%
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
grade 3 bilirubinemia 0%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
50 mg OD
headache 53.8%
upper respiratory tract infection 38.5%
diarrhoea 30.8%
NCT01499199 · Phase 3 · registry result, not featured evidence
50mg BID
diarrhoea 21.4% (placebo 12.5%)
headache 21.4% (placebo 6.3%)
lymphadenopathy 21.4% (placebo 0%)
NCT01568892 · Phase 3 · registry result, not featured evidence
cns disturbances 0%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
50 mg od
low haemoglobin 6.9%
NCT02245022 · Phase 2/3 · registry result, not featured evidence
50 mg BID
abnormal loss of weight 10%
blood pressure increased 10%
headache 10%
NCT05630872 · Phase 2 · registry result, not featured evidence
acute psychosis 1.5% (placebo 0%)
incident pulmonary tuberculosis 1.5% (placebo 0%)
acute kidney injury 0% (placebo 3.1%)
NCT03991013 · Phase 2 · registry result, not featured evidence
insomnia 5.7% (placebo 0%)
NCT03851588 · Phase 2 · registry result, not featured evidence
haemoglobin decreased 33.3%
alanine aminotransferase increased 16.7%
aspartate aminotransferase increased 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 50%
alanine aminotransferase increased 16.7%
blood bilirubin increased 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 83.3%
neutrophil count decreased 50%
acne infantile 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 42.9%
blood bilirubin increased 35.7%
dermatitis diaper 21.4%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 56.3%
neutrophil count decreased 31.3%
blood bilirubin increased 25%
NCT05406583 · Phase 1 · registry result, not featured evidence
hypokalaemia 71.4% (placebo 71.4%)
hypoglycaemia 42.9% (placebo 71.4%)
vivid dreams 28.6% (placebo 0%)
NCT04771754 · Phase 1 · registry result, not featured evidence
hypokalaemia 62.5% (placebo 71.4%)
cold 25% (placebo 14.3%)
bloating 12.5% (placebo 0%)
NCT04771754 · Phase 1 · registry result, not featured evidence
50mg/25mg
headache 6.3%
vessel puncture site bruise 6.3%
vomiting 6.3%
NCT03984838 · Phase 1 · registry result, not featured evidence
h
diarrhoea 26.7%
upper respiratory tract infection 26.4%
nausea 23%
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 31 more results
headache 6.7%
diarrhoea 4.3%
nasopharyngitis 4.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.4%
headache 6.4%
diarrhoea 5.4%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 3.9%
headache 1.9%
back pain 1.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 7%
arthralgia 0%
back pain 0%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.4%
headache 6.5%
diarrhoea 4.5%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.4%
back pain 3.7%
diarrhoea 3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.8%
headache 5.5%
arthralgia 5.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
back pain 2.3%
arthralgia 1.7%
nasopharyngitis 1.7%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 8.3%
arthralgia 1.2%
diarrhoea 1.2%
NCT02397096 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.4%
nasopharyngitis 5.2%
diarrhoea 4.4%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 6.1%
diarrhoea 5.2%
nasopharyngitis 4.7%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.5%
diarrhoea 11.4%
nasopharyngitis 10%
NCT01815736 · Phase 3 · registry result, not featured evidence
diarrhoea 23%
headache 22.7%
upper respiratory tract infection 20.2%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 3.5%
headache 2.8%
arthralgia 1.4%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.2%
cough 2.5%
syphilis 2.5%
NCT01797445 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 14.6%
headache 11%
anaemia 7.3%
NCT01705574 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.3%
headache 17%
nausea 14.9%
NCT01705574 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.9%
back pain 8.2%
diarrhoea 7.3%
NCT02616783 · Phase 3 · registry result, not featured evidence
diarrhoea 25.7%
upper respiratory tract infection 21.1%
nausea 16.8%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
cough 4.4%
syphilis 4.4%
upper respiratory tract infection 3.3%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
diarrhoea 33.9%
upper respiratory tract infection 21.2%
headache 13.8%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
upper respiratory tract infection 20.5%
nasopharyngitis 19.2%
bronchitis 13.7%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 36.4%
insomnia 21.2%
headache 18.2%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.3%
upper respiratory tract infection 9.9%
diarrhoea 9.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.2%
nasopharyngitis 10.2%
NCT01495702 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.3%
nasopharyngitis 10.3%
NCT01495702 · Phase 3 · registry result, not featured evidence
diarrhoea 28%
upper respiratory tract infection 24.4%
nausea 22.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 20.8%
insomnia 12.5%
anxiety 10.4%
NCT01533259 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 36%
headache 24%
vomiting 20%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
nausea 22.3%
diarrhoea 17%
fatigue 16.1%
NCT01497899 · Phase 2 · registry result, not featured evidence
diarrhoea 27.1%
fatigue 16.7%
headache 14.6%
NCT00869557 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2/3 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dPopulation context differs: prior_therapy differs (experienced versus naive).
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fTrial phases differ: Phase 4 versus Phase 3.
  7. gPopulation comparability has not been reviewed for 39 of these studies.
  8. hPopulation comparability has not been reviewed for 34 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dolutegravir

Time to Viral Suppression 0.92 vs 2.79 DRV + RTV months50 mg once daily
time to event · months
NCT01449929 · Phase 3 · converted to months from 28 days as posted
show 3 more results
0.92 vs 2.76 EFV/TDF/FTC months*50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3 · converted to months from 28 days as posted
0.95 vs 0.95 DTG + TDF/FTC months @ 144wk*
NCT02831673 · Phase 3 · registry result, not featured evidence · combination · converted to months from 29 days as posted
0.95 vs 0.95 DTG + TDF/FTC months*
NCT02831764 · Phase 3 · registry result, not featured evidence · combination · converted to months from 29 days as posted
Virologic Failure 2.7% (n=414) vs 1.9% (n=419) EFV/TDF/FTC50 mg plus 600/300 mg once daily
event count · % of participants
ACTG virologic failures
NCT01263015 · Phase 3 · combination · HIV · phase 3 · converted to % from 11 Participants as posted
Symptom Bother -3.2 vs -2.19 DRV + RTV score @ 4wk50 mg once daily
absolute change · score
NCT01449929 · Phase 3
show 3 more results
-2.71 vs -1.65 DRV + RTV score @ 24wk50 mg once daily
NCT01449929 · Phase 3
-2.46 vs -0.77 DRV + RTV score @ 48wk50 mg once daily
NCT01449929 · Phase 3
-1.818 vs -1.246 EFV/TDF/FTC score50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
HIV-1 RNA Less Than 50 80.8% (n=411) vs 76.4% (n=411) RTG @ 96wk50 mg Once a Day
event count · % of participants
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 332 Participants as posted
HIV-1 RNA Less Than 400 89.8% (n=411) vs 86.6% (n=411) RTG @ 48wk50 mg Once a Day
event count · % of participants
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 369 Participants as posted
show 1 more result
82.2% (n=411) vs 78.1% (n=411) RTG @ 96wk*50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 338 Participants as posted
CD4+ 80.1 vs 75.6 DRV + RTV cells/uL @ 4wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 4, n=237, 236
NCT01449929 · Phase 3
CD4+ 126.9 vs 118.8 DRV + RTV cells/uL @ 8wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 8, n=236, 236
NCT01449929 · Phase 3
CD4+ 135.2 vs 131.8 DRV + RTV cells/uL @ 12wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 12, n=234, 228
NCT01449929 · Phase 3
CD4+ 156.8 vs 146.1 DRV + RTV cells/uL @ 16wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 16, n=227, 227
NCT01449929 · Phase 3
CD4+ 165.1 vs 164.3 DRV + RTV cells/uL @ 24wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 24, n=233, 227
NCT01449929 · Phase 3
CD4+ 206.1 vs 186.5 DRV + RTV cells/uL @ 36wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 36, n=232, 218
NCT01449929 · Phase 3
CD4+ 243.8 vs 215.4 DRV + RTV cells/uL @ 48wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 48, n=227, 212
NCT01449929 · Phase 3

+ 73 further endpoints in the CSV export.

Elvitegravir

LDL-C -16.54 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.94 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL -24.74 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.31 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
CD4+ 13.9 cells/uL
absolute change · cells/uL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
18 cells/uL
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
18 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 40 Copies 89.7% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
93.3% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
92.8% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
93.3% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Ge50 Copies 1.6% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
1.8% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 97.2% (n=959) vs 93.1% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 20 Copies 93.5% (n=959) vs 90.4% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 20 Copies 90.6% (n=959) vs 85.3% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
responder rate · % of participants
NCT01815736 · Phase 3 · registry result, not featured evidence
show 5 more results
82.4% (n=431) vs 80.7% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3 · registry result, not featured evidence
78.7% (n=431) vs 76.8% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3 · registry result, not featured evidence
86.4% (n=435) vs 87.3% (n=432) E/C/F/TDF @ 48wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
84.4% (n=435) vs 83.6% (n=432) E/C/F/TDF @ 96wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
84.6% (n=435) vs 80.1% (n=432) E/C/F/TDF @ 144wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA Less Than 50 Copies 84.5% (n=278) @ 96wk
responder rate · % of participants
No placebo or comparator arm
NCT01705574 · Phase 3 · registry result, not featured evidence
show 11 more results
78.8% (n=33) @ 48wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
88.9% (n=33) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
82.2% (n=73) @ 48wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
90.7% (n=73) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
84.8% (n=33) @ 24wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
90.4% (n=73) @ 24wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
100% (n=48) @ 12wk
NCT01533259 · Phase 3 · registry result, not featured evidence
100% (n=48) @ 24wk
NCT01533259 · Phase 3 · registry result, not featured evidence
100% (n=48) @ 48wk
NCT01533259 · Phase 3 · registry result, not featured evidence
88% (n=50) @ 24wk
NCT01721109 · Phase 2/3 · registry result, not featured evidence
88% (n=50) @ 48wk
NCT01721109 · Phase 2/3 · registry result, not featured evidence
CD4+ 265 vs 35 GEN cells/uL
absolute change · cells/uL
Extension (open-label)
NCT01705574 · Phase 3 · registry result, not featured evidence
Lumbar Spine BMD 2.237% (n=102) vs -0.104% (n=54) Stay on Baseline Regimen @ 48wk
percent change · % of baseline
NCT02616783 · Phase 3 · registry result, not featured evidence
show 1 more result
1.625% (n=104) vs -0.027% (n=54) Stay on Baseline Regimen @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence
Hip BMD 1.33% (n=101) vs -0.726% (n=54) Stay on Baseline Regimen @ 48wk
percent change · % of baseline
NCT02616783 · Phase 3 · registry result, not featured evidence
show 1 more result
0.808% (n=103) vs -0.537% (n=54) Stay on Baseline Regimen @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dolutegravir's landscape · Elvitegravir's landscape